

Zydus Cadila expands the Scientific Advisory Board at Zydus Research Centre

Ahmedabad, December 15, 2011

Zydus Cadila today announced that Prof. Dr. Rolf G. Werner, former Corporate Senior Vice President, of the Corporate Division Biopharmaceuticals at Boehringer Ingelheim, and Dr. Balu Balasubramanian Former Managing Director of Bristol-Myers Squibb-Biocon Research Center have accepted the invitation to join the Scientific Advisory Board of Zydus Cadila.

Prof. Werner is worldwide well respected for his seminal contributions to biotechnology during his tenure at Boehringer Ingelheim as well as at the Universities of Tuebingen and Chiang Mai for more than 40 years. Prof. Werner is one of the pioneers in pharmaceutical biotechnology in Europe. He built up the global biopharmaceutical business for development and manufacturing of high quality biopharmaceuticals at Boehringer Ingelheim and managed it successfully for more than three decades. He was responsible for the first product-Actilyse- developed in recombinant mammalian cell cultures in only 4 years and for the largest biotech plant in Europe at that time with 6 x 15,000 liters capacity, designed and constructed in only 18 months. He has published more than 150 scientific papers, 15 scientific films and owns numerous patents.

Prof. Werner's expertise in the field of biopharmaceuticals will prove invaluable for Zydus Cadila as it aspires to step up major investments into biotechnical manufacturing and research of high quality biopharmaceutical medicines. Zydus Cadila has received approval to market a biogeneric version of erythropoietin for anemia in 2011 and has recently launched Pegstim (pegylated filgrastim) and PegiHep (peg-interferon alfa-2b) and is currently developing a portfolio of 17 biopharmaceuticals that includes also biosimilars.

Dr. Balu Balasubramanian who also joins the advisory board has been the Managing Director of the Bristol-Myers Squibb -Biocon Research Center . Dr. Balu N. Balasubramanian has considerable expertise in the areas of Medicinal Chemistry, Drug Discovery and Development Research. During his tenure at Bristol-Myers Squibb for the past 26 years, he has led several programmes in different disease targets for the indications that included cholesterol lowering, stroke, anti-thrombotic, anti fungal/anti-infective, cytotoxic & kinase inhibitors for anti-cancer and immunological disorders. Dr. Balasubramanian's team has identified and nominated clinical candidates in many of these drug development programmes.

Zydus Cadila currently has 8 NMEs in various phases of development and 15 active drug discovery programmes. The research and development efforts are focused on discovering new medicines for treating diabetes, obesity, cardiovascular risk, inflammation and cancer. Zydus Cadila has capabilities to conduct drug discovery and development right from idea to proof-of-concept in various *in-vitro*, *in-vivo* models and clinical trials. Zydus Cadila aims to be an innovation-driven, research-based global operating pharmaceutical company by the year 2020, with the vision to improve the health and welfare of the people.

###